Instrument Inactif

Autres langues Signal Genetics Inc Nasdaq

Actions

US8266401046

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

22/09	Selon RBC, Lumvoa de Viridian Therapeutics démarre « plus fortement » que prévu	MT
22/09	Viridian Therapeutics, Inc. : RBC Capital Markets maintient sa recommandation à l'achat	ZM

Autres langues

22/09	Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
16/09	Sling Therapeutics raises $123 million to advance thyroid eye disease drug
02/09	Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
31/08	Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
07/08	Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
06/08	Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $284,000
06/08	Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
30/06	Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
29/06	Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
29/06	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
29/06	Aktien New York Ausblick: Nasdaq erholt - Comcast-Aufspaltung beflügelt Branche
29/06	Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
29/06	DRI Healthcare to Pay Viridian US$75 Million as FDA Approves Lumvoa For Thyroid Eye Disease
29/06	Borsa Usa, attesa in rialzo con futures Nasdaq su allentamento tensioni Medio Oriente
29/06	Viridian Therapeutics' Lumvoa Gets FDA Approval to Treat Thyroid Eye Disease; Shares Up Pre-Bell
29/06	Nasdaq futures lead Wall St higher as Middle East tensions ease
27/06	US FDA greenlights Viridian's thyroid eye disease drug
27/06	US FDA greenlights Viridian's eye disease drug
27/06	Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
27/06	Viridian Therapeutics Receives U.S. FDA Approval and Launches Lumvoa for the Treatment of Thyroid Eye Disease
26/06	Viridian Therapeutics Says FDA Approves Lumvoa to Treat Thyroid Eye Disease
28/05	Viridian Therapeutics, Inc. Announces Voluntary Prepayment and Termination of Loan Agreement
27/05	Viridian Therapeutics to Participate in Upcoming June Investor Conferences
26/05	Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug